Alpha Tau Medical Ltd. (NASDAQ:DRTS) Stock Has Consensus Target Price of $15.40 According to Analysts

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) have received a consensus rating of “Hold” from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $15.40.

A number of equities analysts have recently weighed in on the stock. Benchmark reissued a “buy” rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. HC Wainwright upped their price objective on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Friday, July 17th. Barclays lifted their target price on Alpha Tau Medical from $17.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, September 3rd. Finally, Zacks Research cut Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 1st.

Alpha Tau Medical Stock Down 1.6%

Alpha Tau Medical stock opened at $14.54 on Friday. The company’s 50 day simple moving average is $13.99 and its 200 day simple moving average is $10.90. Alpha Tau Medical has a fifty-two week low of $3.43 and a fifty-two week high of $15.79. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -13.98 and a beta of 1.20. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.09 and a quick ratio of 7.79.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Monday, August 10th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.36). As a group, sell-side analysts anticipate that Alpha Tau Medical will post -1.05 EPS for the current year.

Insider Buying and Selling at Alpha Tau Medical

In related news, CFO Raphi Levy sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $12.00, for a total value of $240,000.00. Following the completion of the transaction, the chief financial officer directly owned 90,180 shares in the company, valued at approximately $1,082,160. The trade was a 18.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 62,871 shares of company stock worth $823,108. Insiders own 39.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC acquired a new position in shares of Alpha Tau Medical in the first quarter valued at approximately $286,000. Principal Financial Group Inc. acquired a new stake in shares of Alpha Tau Medical during the first quarter worth $132,000. Finally, Everhart Financial Group Inc. acquired a new stake in shares of Alpha Tau Medical during the second quarter worth $126,000. Institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is an Israel-based biotechnology and medical technology company developing targeted alpha radiation therapies for the treatment of solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver localized alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses radium-224 sources placed into or near a tumor. As the radium decays, its short-range alpha-emitting products are intended to diffuse through the tumor and destroy cancer cells.